Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind active-controlled multicenter study of OT-601-C for postoperative ocular inflammation after cataract surgery
CTR20240214Phase 2Completed
- Sponsor
- Ocumension Biotech
- Start
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of OT-601-C in Postoperative ocular inflammation and cataract (2 arms), sponsored by Ocumension Biotech. Primary endpoints: Mean time to recovery of anterior chamber cell grade 0 in the study eye, Mean time to recovery of anterior chamber cell grade less than or equal to 0.5+ in the study eye and 10 more. Started Jun 2024; status: completed.
02
Drugs
OT-601-C
03
Conditions
Postoperative ocular inflammationcataract
Beyond the preview
Go deeper on CTR20240214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240214.